Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis. 1979

J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys

Vancomycin is a useful antimicrobial agent in patients undergoing chronic hemodialysis treatment; its efficacy in chronic peritoneal dialysis (CPD) has not been established. Serum (VS) and peritoneal fluid (VPF) vancomycin concentrations were measured in two CPD patients with staphylococcal peritonitis. Half-life of VS agreed with the half-life of VPF in each patient, and the VS/VPF ratio was 1.27 in both patients. Distribution volumes were 37.2 and 58.7 l, values approximating total body water in these patients. VS and VPF persisted in the therapeutic range (greater than 5 microgram/ml) for more than 16 days. In one patient, mean peritoneal clearacne was 9.8 ml/min, and overall drug clearance averaged 2.3 ml/min; in the other patient, overall clearance was 2.1 ml/min. These results indicate that therapeutic vancomycin levels can be maintained for more than 16 days with a single 1 g intravenous dose in patients receiving intermittent CPD, as is the case for hemodialysis patients. Because of this, parenteral vancomycin is useful in the treatment of staphylococcal peritonitis in CPD patients.

UI MeSH Term Description Entries
D008297 Male Males
D010530 Peritoneal Dialysis Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or an intermittent procedure. Dialyses, Peritoneal,Dialysis, Peritoneal,Peritoneal Dialyses
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001202 Ascitic Fluid The serous fluid of ASCITES, the accumulation of fluids in the PERITONEAL CAVITY. Peritoneal Effusion,Peritoneal Fluid,Ascitic Fluids,Effusion, Peritoneal,Fluid, Ascitic,Fluid, Peritoneal,Peritoneal Effusions,Peritoneal Fluids
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013203 Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. Infections, Staphylococcal,Staphylococcus aureus Infection,Staphylococcal Infection,Staphylococcus aureus Infections
D014640 Vancomycin Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. AB-Vancomycin,Diatracin,VANCO-cell,Vanco Azupharma,Vanco-saar,Vancocin,Vancocin HCl,Vancocine,Vancomicina Abbott,Vancomicina Chiesi,Vancomicina Combino Phar,Vancomicina Norman,Vancomycin Hexal,Vancomycin Hydrochloride,Vancomycin Lilly,Vancomycin Phosphate (1:2),Vancomycin Phosphate (1:2), Decahydrate,Vancomycin Sulfate,Vancomycin-ratiopharm,Vancomycine Dakota,Hydrochloride, Vancomycin,Sulfate, Vancomycin

Related Publications

J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
November 1981, American journal of hospital pharmacy,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
December 1982, International journal of clinical pharmacology, therapy, and toxicology,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
October 1980, Clinical toxicology,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
January 2003, Journal of toxicology. Clinical toxicology,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
January 1979, Nephron,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
January 1984, American journal of nephrology,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
December 1997, Journal of the American Society of Nephrology : JASN,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
June 1985, British journal of clinical pharmacology,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
July 1983, American journal of kidney diseases : the official journal of the National Kidney Foundation,
J C Ayus, and J F Eneas, and T G Tong, and N L Benowitz, and P Y Schoenfeld, and K L Hadley, and C E Becker, and M H Humphreys
September 1982, American heart journal,
Copied contents to your clipboard!